Boryung Pharm (003850) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Boryung Pharm KRW 14,064, price KRW 8,280, upside +69.9%, quality 48 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Boryung Pharm for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 7,300 KRW – 20,677 KRW · fair‑value band 9,845 KRW – 18,283 KRW · the 8,280 KRW price screens below the 14,064 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Boryung Pharm in your weekly email
Every Wednesday you see whether Boryung Pharm is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Boryung Corporation engages in the manufacture and sale of pharmaceutical products in South Korea and internationally. It offers prescription drugs for hypertension, dyslipidemia, and diabetes drugs. The company was formerly known as Boryung Pharmaceutical Co., Ltd. and changed its name to Boryung Corporation in March 2022.
Show more
Boryung Corporation engages in the manufacture and sale of pharmaceutical products in South Korea and internationally. It offers prescription drugs for hypertension, dyslipidemia, and diabetes drugs. The company was formerly known as Boryung Pharmaceutical Co., Ltd. and changed its name to Boryung Corporation in March 2022. Boryung Corporation was founded in 1957 and is headquartered in Seoul, South Korea.
Stock analysis
Boryung Pharm (003850) currently trades at 8,280 KRW, while our model-based Fair Value estimate is 14,064 KRW, implying the stock looks roughly 41.1% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 19,464 KRW per share, and 18 of the 24 models we run sit above the 8,280 KRW price.
Bear case: the Economic Profit group reads lowest at 4,978 KRW, and 6 of the 24 models stay below the price. Evidence for this calculation is medium.
Scenario range: 9,845 KRW (bear) to 18,283 KRW (bull), the price of 8,280 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Boryung Pharm reported revenue of 1.0T KRW in FY2025 versus 627B KRW in FY2021, a compound +12.9%/yr. Reported net income was 64.3B KRW in FY2025, compounding +10.6%/yr from FY2021.
Key figures
Market cap 699B KRW (≈ $514M) · P/S ratio 0.67 · Dividend yield 1.9% · Net margin 6.3% · Return on equity 12.8% · Return on assets (EBIT) 5.9% · Operating margin 7.9% · Revenue (TTM) 1.0T KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (medium confidence).
What moves the price
The share trades about 22% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 70%, 003850 screens cheaper than that median.
Fair Value models
Bear 9,845 KRWFair Value 14,064 KRWBull 18,283 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.89/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+0.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.6%
Start year 2020 (pandemic)
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.7%
’11
’12
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+5.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+3.2%
Dividend (yield on the price)1.9%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.7% → 6%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−7.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about −8.9% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 628 stocks
Beats the industry median on 7/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score48 · Below median
Fair Value upside+70% · Top 25%
Profitability
Return on equity (TTM)13% · Above median
Return on assets4% · Above median
Net margin (TTM)10% · Above median
Operating margin (TTM)8% · Below median
Growth and dividend
Revenue growth6% · Above median
Dividend yield (TTM)1.9% · Above median
Balance sheet
Debt / equity0.29× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Boryung Pharm Fair Value". https://www.fairvalue-calculator.com/stock/003850
Frequently asked questions
Is Boryung Pharm (003850) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 14,064 KRW versus a price of 8,280 KRW, about +70% upside (undervalued).
What is the fair value of 003850?
Our model-based fair value for Boryung Pharm is 14,064 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 8,280 KRW.
What is the quality score of 003850?
Boryung Pharm has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Boryung Pharm (003850)?
Our model-based price target is the fair value of 14,064 KRW (as of Sep 24, 2026) from 24 valuation models. Cautious scenario 9,845 KRW, optimistic scenario 18,283 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Boryung Pharm stock forecast for 2026?
Our models put fair value at 14,064 KRW, about +70% upside versus a price of 8,280 KRW (undervalued). Cautious scenario 9,845 KRW, optimistic scenario 18,283 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Boryung Pharm (003850)?
Boryung Pharm reported trailing-twelve-month revenue of about 1.0T KRW (latest available figure, as of Sep 24, 2026).
Does Boryung Pharm pay a dividend?
Boryung Pharm currently shows a dividend yield of about 1.93% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Boryung Pharm (003850)?
For today's price to be fair in a discounted-cash-flow model, Boryung Pharm would have to grow free cash flow by -7.1 % per year for five years (discount rate 10.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +12.6 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 003850 use?
Our models discount Boryung Pharm at 10.2 %: a base by market capitalisation (small), damped by beta 0.33, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Boryung Pharm that is -7.1 % per year a year over ten years, using the same discount rate (10.2 %) and the same formula as our fair value.
How much growth has Boryung Pharm (003850) delivered so far?
Over the past 5 years revenue at Boryung Pharm grew +12.6 % a year. The price currently implies -7.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Boryung Pharm (003850) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Boryung Pharm (-7.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Boryung Pharm (003850)?
The free-cash-flow yield on the price is 14.76 %: that much free cash flow Boryung Pharm produces per unit of market value. When it exceeds the discount rate of our models (10.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Boryung Pharm (003850)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Boryung Pharm it is 14,064 KRW per share (as of Sep 24, 2026), against a price of 8,280 KRW. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Boryung Pharm stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 003850 trades below its calculated fair value: price 8,280 KRW, fair value 14,064 KRW, a gap of about +70% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 003850?
No. The price is what the market pays today (8,280 KRW); the fair value is what the company's own numbers justify (14,064 KRW). For Boryung Pharm the two are 5,784 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Boryung Pharm worth?
The market values Boryung Pharm at about 699B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 8,280 KRW; our models calculate a fair value of 14,064 KRW per share.
What do the bullish and bearish scenarios say about 003850?
Our models span a range for Boryung Pharm: cautious scenario 9,845 KRW, base 14,064 KRW, optimistic 18,283 KRW per share (as of Sep 24, 2026, price 8,280 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Boryung Pharm (003850)?
Balance-sheet figures for Boryung Pharm (as of Sep 24, 2026): return on equity 12.8%, debt of 0.29 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is 003850 from its 52-week high?
Boryung Pharm trades at 8,280 KRW, about 22% below its 52-week high of 10,680 KRW and 5% above the low of 7,850 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 14,064 KRW is for.
Which stocks are comparable to Boryung Pharm?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Boryung Pharm stock attractive at the current price?
The data as of Sep 24, 2026: price 8,280 KRW, calculated fair value 14,064 KRW (+70%), Quality Score 48/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 003850 calculated?
We run Boryung Pharm through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 14,064 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Boryung Pharm currently trades 70 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Boryung Pharm (003850)?
The closing price on Sep 23, 2026 was 8,280 KRW. Our model-based fair value is 14,064 KRW, about +70% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Boryung Pharm right now?
The price is below even our cautious bear case (9,845 KRW). The market is more pessimistic than our downside scenario. Solid quality (48/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (9,845 KRW to 18,283 KRW) leaves room in how you read the outcome.
Key figures of Boryung Pharm
How large is the market capitalisation of Boryung Pharm (003850)?
The market capitalisation of Boryung Pharm is 699B KRW (≈ $514M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Boryung Pharm (003850)?
The price-to-sales ratio of Boryung Pharm is 0.67 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Boryung Pharm (003850)?
The dividend yield of Boryung Pharm is 1.9%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Boryung Pharm (003850)?
The net margin of Boryung Pharm is 6.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Boryung Pharm (003850)?
The return on equity (ROE) of Boryung Pharm is 12.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Boryung Pharm (003850)?
On an EBIT basis the return on assets of Boryung Pharm is 5.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Boryung Pharm (003850)?
The operating margin of Boryung Pharm is 7.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Boryung Pharm (003850)?
Revenue at Boryung Pharm is growing +6.2% versus a year earlier (3y avg +10.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Boryung Pharm (003850)?
Earnings per share at Boryung Pharm are growing +122% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Boryung Pharm (003850) carry?
The net debt of Boryung Pharm is 83.5B KRW (fiscal year 2025, ≈ 0.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Boryung Pharm in the live analysis
One click puts Boryung Pharm on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
